logo-loader
viewMedlab Clinical Ltd

Medlab Clinical ahead of expectations with Phase 2 Depression Trial for NRGBiotic™

Study timelines are progressing as planned and at this point the trial should complete ahead of expectations.

Medlab Clinical Ltd - Medlab Clinical ahead of expectations with Phase 2 Depression Trial for NRGBiotic™
The company is seeking to expand commercialisation opportunities

Medlab Clinical Ltd (ASX:MDC) is progressing ahead of expectations with a Phase 2 Depression Trial using a unique self-branded, in pharmacy formulation, NRGBiotic™ from its Nutraceuticals range.

Current results are suggesting the trial will complete earlier than originally required.

The impact of the trials progressing ahead of expectations marks an important milestone to expanded commercialisation opportunities that drug registration would offer.

Adjunct to depression treatment

Trials focus on an adjunct to depression treatment which is globally estimated to be a $US864 million market in 2015 and is expected to reach $US1.2 billion by 2024.

Overall, the global depression market is estimated to be $US15.6 billion, at 2.4% CAGR.

The plan for NRGBiotic™ is to follow a drug development pathway, whereby after this trial, Medlab would expect results publication, product optimisation and further trial work.

Medlab plans at the end of this trial to continue talks with the TGA for drug pathway development which would be critical for future NRGBiotic™ plans.

Team “very excited”

Medlab CEO Dr Sean Hall said, “Progression to date has the Board and research team very excited and optimistic.

“The study timelines are progressing as planned, and at this point the trial should complete ahead of expectations.”

Shares have been up as much as 4% in early trade to 38.5 cents.

In July 2018 Medlab announced the start of recruitment for an Australian Human Research Ethics and TGA approved Clinical Trial.

It is an n=150 study to follow on from previous trials investigating the use of NRGBiotic™ versus placebo as an adjuvant to SSRI and or SNRI, which are common anti-depressant medications, for people diagnosed with depression that were getting little or no relief from standard medical treatment for major depression.

Strict inclusion criteria

Progression of the Phase 2 trial to date with principal investigators Dr Esben Strodl and Dr Matthew Bambling at Queensland University of Technology, Brisbane, has seen about 1,500 potential candidates interviewed.

However, due to the strict inclusion criteria, to date 90 patients have been randomised and entered into the study.

Medlab CEO Dr Sean Hall said, “We understand this is a much-needed trial for a significant patient group, we further understand depression is an illness that can have life-long repercussions.

“Patient demand for trial entry exceeded our initial thoughts, and whilst we would ultimately like to help everyone, the trial entry criteria has specific requirements.”

National rollout

NRGBiotic™ is a multi-patented probiotic available throughout Australian pharmacies as part of the national rollout that began in the first half of 2019.

Since the trial recruitment announcement there have been approximately 13,500 units sold to Australians outside the trial cohort.

Hall said, “We are looking at, in short, developing a medication that hopefully will address a unique cohort, those over 18 years of age, who have been on anti-depressants, with little to no improvement in symptoms and/or quality of life.

“Presently this treatment-resistant group accounts for about one-third of all medicated depression patients.”

Potential efficacious trendline

While trial participants and researchers are blinded to the active or placebo treatment, preliminary reports highlight a potential efficacious trendline that may see the trial complete at 130 patients to report against statistically relevant powering to support the study outcomes.

As the Christmas season approaches, recruitment for the study will stop to ensure those patients under investigation are sufficiently monitored, with recruitment expected to recommence in mid-January 2020.

Hall said, “Depression is a global epidemic, affecting just over 5% of the world’s population, scarier though, health authorities are expecting this to rise to 7% within the immediate foreseeable future, resulting in a growing global patient group where medication strategies potentially will only work on two-thirds of the patient group.

“We, (Medlab) believe we can offer novel, replicable and reliable intervention strategies that will reduce symptoms and improve quality of life.”

Quick facts: Medlab Clinical Ltd

Price: 0.345 AUD

ASX:MDC
Market: ASX
Market Cap: $74.3 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Medlab Clinical Ltd named herein, including the promotion by the Company of Medlab Clinical Ltd in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Medlab Clinical forges ahead in new vitamin trials for chronic illnesses

Medlab Clinical Ltd (ASX:MDC) chief executive officer Sean Hall tells Proactive Investors how the company is tapping into new areas of its “therapeutic toolkit” to better assist those with chronic health conditions.   Hall says there has been a shortfall in the standard of...

on 8/5/19

4 min read